| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-2161 | |
| Phytochemical name or plant extracts | Sophoflavescenol | |
| PMID | 22210035 | |
| Literature evidence | This study examined the in vitro cytotoxic activity and in vivo antitumor activity as well as intracellular apoptotic capacities of a prenylated flavonol, sophoflavescenol from Sophora flavescens, to evaluate prospective anti-tumorigenic drugs, and antitumor potential. | |
| IUPAC name | 3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)chromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Prenylated flavonol | |
| Source of phytochemicals or plant Extracts | Sophora flavescens | |
| Geographical availability | Altay, Amur, China North-Central, China South-Central, China Southeast, Chita, Hainan, Inner Mongolia, Irkutsk, Japan, Khabarovsk, Korea, Manchuria, Mongolia, Primorye, Qinghai, Taiwan, Tibet, Xinjiang | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Lung cancer, Leukemia | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | >150 µg/mL against MCF-7 | |
| Potency | Despite the small effect on human breast adenocarcinoma (MCF-7), sophoflavescenol showed cytotoxicity against human leukaemia (HL-60), Lewis lung carcinoma (LLC), and human lung adenocarcinoma epithelial (A549) cells. | |
| Cell line/ mice model | MCF-7, HL-60, LLC, A549 | |
| Additional information | The findings show that the antioxidant, anti-inflammatory, and apoptotic activities of sophoflavescenol might contribute to the antitumor activity without severe side effects, highlighting its potential for chemoprevention and/or anticancer drugs due to multi-effective targets in almost all stages of tumorigenesis, including initiation, promotion, and progression. | |
| PubChem ID | 9929189 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:518831-1 | |
| Safety | NA |